About Information Provided on This Site

The information provided on our website 'Kabutan.com' is not intended to constitute investment solicitation or investment advisory services.
All investment decisions should be made at your own discretion and judgment.
The data on our website is provided by Tokyo Stock Exchange, Osaka Exchange, Nagoya Securities Exchange, JPX Market Innovation & Research, Japannext, and other sources.
Copyright of the Nikkei Stock Average belongs to Nikkei Inc. Stock price charts displayed on Kabutan.com are provided solely for the purpose of reviewing historical price movements of the securities.
These charts neither suggest nor guarantee future price movements of the securities and do not constitute recommendations to buy or sell.
In our financial results coverage, the term 'Surprise Results' identifies securities that demonstrate a significant degree of surprise in their earnings announcements.
This significance is quantitatively assessed based on multiple factors, including: the nature of the announcement (full-year or quarterly results); types of revisions (earnings or dividend forecasts); and numerical analysis comparing the announced results with both the company's previous forecasts and historical performance.
The 'Surprise Ranking' presents these results in order of their calculated surprise factor. Please note that neither these results nor rankings are intended to suggest or guarantee future performance of the listed securities, nor should they be construed as recommendations to buy or sell.
minkabu the infonoid
(C) 2024 MINKABU THE INFONOID, Inc.
kabutan

Takeda Pharmaceutical Company Limited(4502) Summary

4502
TSE Prime
Takeda Pharmaceutical Company Limited
4,477
JPY
-63
(-1.39%)
Apr 4, 3:30 pm JST
30.65
USD
Apr 4, 2:30 am EDT
Result
PTS
outside of trading hours
Summary Chart Historical News Financial Result
PER
59.7
PBR
0.95
Yield
4.38%
Margin Trading Ratio
18.16
Stock Price
Apr 4, 2025
Opening Apr 4, 9:00 am
4,474 JPY 30.59 USD
Previous Close Apr 3
4,540 JPY 30.83 USD
High Apr 4, 9:32 am
4,513 JPY 30.88 USD
Low Apr 4, 9:02 am
4,437 JPY 30.33 USD
Volume
8,950,800
Trading Value
0.04T JPY 0.27B USD
VWAP
4472.03 JPY 30.62 USD
Minimum Trading Value
447,700 JPY 3,065 USD
Market Cap
7.12T JPY 0.05T USD
Number of Trades
14,755
Liquidity & Number of Trades
As of Apr 4, 2025
Liquidity
High
1-Year Average
4,652
1-Year High Aug 6, 2024
24,081
Margin Trading
Date Short Interest Long Margin Positions Ratio
Mar 28, 2025 207,600 1,288,600 6.21
Mar 21, 2025 238,300 1,528,800 6.42
Mar 14, 2025 182,100 2,156,200 11.84
Mar 7, 2025 228,900 2,338,900 10.22
Feb 28, 2025 163,300 2,882,200 17.65
Company Profile
Takeda Pharmaceutical Company Limited is a leading pharmaceutical company. With the acquisition of Shire, it has become a global industry leader. The company focuses on prescription drugs and is strengthening its development of new cancer medications.
Sector
Pharmaceuticals
Takeda Pharmaceutical Company Limited's main business is the research, development, manufacturing, and sales of pharmaceuticals, with a focus on key business areas including gastroenterology, rare diseases, plasma-derived therapies, oncology, and neuroscience. The company's research and development efforts are concentrated on three areas: innovative biopharmaceuticals in the priority disease areas of gastroenterology and inflammatory diseases, neuroscience, and oncology, along with plasma-derived therapies and vaccines. Takeda is also committed to rare diseases. The company invests in new research and development capabilities and next-generation platforms, leveraging data and digital technologies to enhance innovation quality and accelerate execution. In Japan, Takeda conducts all operations from research and development to sales in-house, while overseas subsidiaries and affiliates handle manufacturing and sales functions in their respective countries.